Anti-PD-L1 nanobody and use thereof
US11274153B2 · kind B2 · utility
0Cited by
6References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2017 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | Sep 23, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/61
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a nanobody against the human programmed death factor PD-LI. The antibody has the function of blocking the binding of PD-LI to the receptor PD-I. Disclosed are the nanobody and the gene sequence encoding the nanobody, the corresponding expression vector and the host cell capable of expressing the nanobody, and the method for producing the nanobody. At the same time, also disclosed is the sequence of the humanized PD-LI nanobody. The humanized nanobody still has the function of blocking the binding of PD-LI to PD-1, and has a relatively high affinity and a relatively good specificity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.